Genscript Biotech Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Genscript Biotech Corporation
B+L/Novaliq Hope Miebo Can Stand Out In Crowded Dry Eye Field
The companies got US FDA approval for the drug, which they said is the only approved medicine that targets tear evaporation rather than tear production, though its mechanism is not fully understood.
Finance Watch: Kenvue, Acelyrin Launch Biggest Biopharma IPOs Of 2023
Public Company Edition: J&J’s consumer health spinout Kenvue grossed $3.8bn in its public market debut and Acelyrin raised $540m in an upsized IPO. Also, Seres accessed $250m in new debt for Vowst commercialization while follow-on offerings raised $325m for ImmunoGen and $240m for Morphic.
US IPO Market In 2022 Even Underperformed Normal Years
INFOGRAPHIC: The number of biopharma offerings in 2022 was far below records set in 2020 and 2021, but also below more normal years of 2018 and 2019. The IPO class of 2022 eked out a positive average return, however.
Stock Watch: Beware The Halo Effect Of Biopharma Leaders
Some entrepreneurs combine talent and experience to produce multiple profitable exits for investors. But there are many who do not, and past success is indeed no guarantee of future performance.
- Contract Research Organization-CRO
- Research, Analytical Equipment & Supplies
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
- Legend Biotech USA Inc.
- Legend Biotech Ireland Limited
- Nanjing GenScript Co Ltd
- Nanjing Legend Biotechnology Co., Ltd.
- GenScript ProBio
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.